Free Trial
NASDAQ:CDT

Conduit Pharmaceuticals 3/28/2025 Earnings Report

Conduit Pharmaceuticals logo
$0.55 -0.02 (-3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$0.55 +0.00 (+0.18%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Conduit Pharmaceuticals EPS Results

Actual EPS
-$20.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Conduit Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conduit Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Conduit Pharmaceuticals' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Conduit Pharmaceuticals Earnings Headlines

Conduit Pharmaceuticals announces Regan appointed as CEO
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
Conduit Pharmaceuticals Announces Leadership Changes
See More Conduit Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Conduit Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Conduit Pharmaceuticals and other key companies, straight to your email.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals (NASDAQ:CDT), a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View Conduit Pharmaceuticals Profile

More Earnings Resources from MarketBeat